Document
IPR2020-01053, No. 2064 Exhibit - Correll et al, Effects of Olanzapine Combined With Samidorphan onWeight Gain in Schizophrenia (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2064 Exhibit - Correll et al, Effects of Olanzapine Combined With Samidorphan onWeight Gain in Schizophrenia (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2049 Exhibit - Seroquel Label (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2049 Exhibit - Seroquel Label (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2131 Exhibit - Declaration of Dr Stephen Stahl (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2131 Exhibit - Declaration of Dr Stephen Stahl (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2087 Exhibit - Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatment with Risperidone (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2087 Exhibit - Mattingly et al, Switching to Lurasidone Following 12 Months ofTreatment with Risperidone (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2061 Exhibit - Meltzer et al, Lurasidone in the Treatment of Schizophrenia ARandomized, Double Blind, Placebo and Olanzapine ControlledStudy (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2061 Exhibit - Meltzer et al, Lurasidone in the Treatment of Schizophrenia ARandomized, Double Blind, Placebo and Olanzapine ControlledStudy (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2137 Exhibit - Weiden, Partial Compliance and Risk of Rehospitalization AmongCalifornia Medicaid Patients with Schizophrenia, PsychiatricServices (P.T.A.B. Mar. 11, 2021...
Cite Document
IPR2020-01053, No. 2137 Exhibit - Weiden, Partial Compliance and Risk of Rehospitalization AmongCalifornia Medicaid Patients with Schizophrenia, PsychiatricServices (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2068 Exhibit - Samalin et al, Clinical potential of lurasidone in the management ofschizophrenia (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2068 Exhibit - Samalin et al, Clinical potential of lurasidone in the management ofschizophrenia (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2139 Exhibit - Tohen et al, Am J Psychiatry (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2139 Exhibit - Tohen et al, Am J Psychiatry (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2133 Exhibit - Declaration of Scott Stancell Condron (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2133 Exhibit - Declaration of Scott Stancell Condron (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2134 Exhibit - Deposition Transcript of Dr Thomas Kosten (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2134 Exhibit - Deposition Transcript of Dr Thomas Kosten (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2046 Exhibit - Kane et al Clozapine for the Treatment Resistant Schizophrenia (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2046 Exhibit - Kane et al Clozapine for the Treatment Resistant Schizophrenia (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2097 Exhibit - Poyurovsky et al, Attentuating Effect of Reboxetine on Appetite andWeight Gain in Olanzapine Treated Schizophrenia Patients (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2097 Exhibit - Poyurovsky et al, Attentuating Effect of Reboxetine on Appetite andWeight Gain in Olanzapine Treated Schizophrenia Patients (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 2051 Exhibit - Thase, Quetiapine monotherapy for bipolar depression (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2051 Exhibit - Thase, Quetiapine monotherapy for bipolar depression (P.T.A.B. Mar. 11, 2021)
+ More Snippets
Document
IPR2020-01053, No. 1001 Exhibit - EX 1001, US Patent No 9,815,827 (P.T.A.B. Jun. 5, 2020)
Cite Document
IPR2020-01053, No. 1001 Exhibit - EX 1001, US Patent No 9,815,827 (P.T.A.B. Jun. 5, 2020)
+ More Snippets
Document
IPR2020-01053, No. 2077 Exhibit - Albright, Three key antipsychotics lose patent protection (P.T.A.B. Mar. 11, 2021)
Cite Document
IPR2020-01053, No. 2077 Exhibit - Albright, Three key antipsychotics lose patent protection (P.T.A.B. Mar. 11, 2021)
+ More Snippets